Janney Montgomery Scott LLC boosted its holdings in Amedisys, Inc. (NASDAQ:AMED) by 16.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 6,907 shares of the health services provider’s stock after buying an additional 952 shares during the period. Janney Montgomery Scott LLC’s holdings in Amedisys were worth $1,633,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the company. California Public Employees Retirement System boosted its holdings in Amedisys by 2.3% in the 3rd quarter. California Public Employees Retirement System now owns 72,524 shares of the health services provider’s stock valued at $17,147,000 after purchasing an additional 1,641 shares during the period. First Trust Advisors LP increased its stake in Amedisys by 354.3% during the third quarter. First Trust Advisors LP now owns 92,435 shares of the health services provider’s stock valued at $21,854,000 after acquiring an additional 72,089 shares during the period. Commonwealth Equity Services LLC raised its holdings in Amedisys by 68.6% in the 3rd quarter. Commonwealth Equity Services LLC now owns 6,872 shares of the health services provider’s stock valued at $1,624,000 after acquiring an additional 2,795 shares in the last quarter. Wells Fargo & Company MN lifted its position in shares of Amedisys by 1.3% in the 3rd quarter. Wells Fargo & Company MN now owns 632,846 shares of the health services provider’s stock worth $149,625,000 after acquiring an additional 7,870 shares during the period. Finally, Bell Bank grew its holdings in shares of Amedisys by 3.4% during the 3rd quarter. Bell Bank now owns 4,467 shares of the health services provider’s stock worth $1,056,000 after purchasing an additional 146 shares in the last quarter. Institutional investors own 79.79% of the company’s stock.

AMED has been the subject of several research reports. Barclays raised their target price on Amedisys from $290.00 to $298.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 3rd. Deutsche Bank Aktiengesellschaft lifted their target price on shares of Amedisys from $260.00 to $275.00 and gave the company a “buy” rating in a research report on Friday, October 30th. Royal Bank of Canada raised their price target on shares of Amedisys from $218.00 to $260.00 and gave the stock an “outperform” rating in a research note on Thursday, July 30th. Oppenheimer lifted their price objective on Amedisys from $250.00 to $260.00 and gave the company an “outperform” rating in a report on Monday, September 21st. Finally, Stephens restated an “equal weight” rating and set a $245.00 target price (up previously from $235.00) on shares of Amedisys in a research report on Thursday, September 10th. Three investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of $248.14.

In related news, insider Sharon Brunecz sold 4,367 shares of Amedisys stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $245.37, for a total value of $1,071,530.79. Following the sale, the insider now owns 22,100 shares of the company’s stock, valued at approximately $5,422,677. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Michael Paul North sold 4,069 shares of the business’s stock in a transaction that occurred on Wednesday, September 9th. The shares were sold at an average price of $230.00, for a total value of $935,870.00. The disclosure for this sale can be found here. Insiders sold a total of 13,386 shares of company stock worth $3,218,600 over the last ninety days. 2.90% of the stock is currently owned by insiders.

NASDAQ AMED opened at $241.10 on Friday. Amedisys, Inc. has a one year low of $132.95 and a one year high of $273.77. The company has a debt-to-equity ratio of 0.40, a current ratio of 0.94 and a quick ratio of 0.94. The firm has a market cap of $7.91 billion, a P/E ratio of 48.32, a P/E/G ratio of 2.72 and a beta of 0.90. The stock’s 50-day moving average is $249.30 and its 200-day moving average is $220.54.

Amedisys (NASDAQ:AMED) last announced its earnings results on Monday, November 2nd. The health services provider reported $1.52 EPS for the quarter, topping the consensus estimate of $1.27 by $0.25. Amedisys had a net margin of 8.22% and a return on equity of 26.41%. Equities analysts anticipate that Amedisys, Inc. will post 6.07 EPS for the current year.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

Read More: How is an ETF different from a mutual fund?

Institutional Ownership by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.